KMT2A and leukemia: The anti-stemness cluster was enriched in epigenetic drugs or combinations targeting BET bromodomains (OTX015), menin-MLL interactions (MI-2), and DOT1L (EPZ-5676), which have demonstrated pre-clinical activity on the NPM1c leukemia-initiating program [22–24].